- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- Oliver Sartor host Dana Rathkopf for a discussion on BMS-986365, a novel androgen receptor ligand-directed degrader for prostate cancer treatment. Dr. Rathkopf discusses the drug's unique dual mechanism of action, which both degrades and competitively inhibits the androgen receptor. She presents data from the phase I/II trial, highlighting the drug's efficacy, particularly in patients without prio...
|
- Details
- Neeraj Agarwal discusses a post-hoc analysis of the TALAPRO-2 Phase III study, which evaluates the efficacy of talazoparib and enzalutamide in metastatic castrate-resistant prostate cancer patients with prior ARPI or docetaxel treatment. The analysis shows promising results for the combination therapy, particularly in patients with HRR-deficient tumors. Dr. Agarwal emphasizes the potential benefit...
|
- Details
- Oliver Sartor interviews Neeraj Agarwal about the CONTACT-02 trial, which compares cabozantinib plus atezolizumab to second ARPI in metastatic castrate-resistant prostate cancer patients. Dr. Agarwal presents the final overall survival results from the study, which shows improved progression-free survival with the combination therapy, particularly in patients with liver or bone metastasis. While o...
|
- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors. Dr. Conteduca discusses the trial design, which randomizes patients to receive either radium-223 followed by docetaxel or vice versa. The primary endpoint is ch...
|
- Details
- Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival an...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about his presentation on T-cell engaging treatments for prostate cancer. Dr. Agarwal discusses the rationale behind T-cell engagers, their potential to bypass the limitations of prostate cancer's cold tumor microenvironment, and the various tumor-associated antigens being targeted. He reviews several bispecific and trispecific T-cell engagers currently in...
|
- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
